Our study demonstrated that Mfsd2a mRNA and protein levels are elevated in NASH patients, hinting at a role of Mfsd2a in limiting NAFLD progression. The gene discussed is MFSD2A; the disease is metabolic dysfunction-associated steatotic liver disease.